REUTERS
August 11, 2020 at 17:16 JST
A health worker takes a break in between conducting COVID- 19 testing through rapid antigen methodology inside a mobile lab in New Delhi, India, on Aug. 10. (AP Photo)
SEOUL--South Korea’s Daewoong Pharmaceutical Co., Ltd., said on Tuesday it received Indian regulatory approval to test its anti-parasitic niclosamide drug to treat COVID-19 patients in an early-stage human trial.
The phase 1 trial, approved by India’s Central Drugs Standard Control Organization (CDSCO), will involve around 30 healthy participants to test safety and kickstart this month, Daewoong said in a statement.
The South Korean drugmaker is testing the drug in partnership with New Delhi-based Mankind Pharma Ltd., which will continue the second and third phases of trials in India on mild and severe coronavirus patients.
Drugmakers worldwide are scrambling to develop treatments for the illness caused by the novel coronavirus, which has killed nearly 739,000 people globally since it first emerged late last year in China.
The trial results from India will be used for export permits in Europe and the United States, said Daewoong. The company is also waiting for a separate phase 1 trial approval from South Korea, Nathan Kim, vice-president at Daewoong’s communications office, told Reuters.
Daewoong had said its anti-viral drug had completely eliminated the novel coronavirus from animals’ lungs during pre-clinical testing.
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.